NABRIVA THERAPEUTICS

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epox... ide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.

#SimilarOrganizations #People #Financial #Event #Website #More

NABRIVA THERAPEUTICS

Social Links:

Linkedin

Industry:

Biotechnology Health Care Medical

Founded:

2001-01-01

Address:

Vienna, Wien, Austria

Country:

Austria

Website Url:

http://www.nabriva.com

Total Employee:

101+

Status:

Active

Contact:

(430) 174-0930

Email Addresses:

[email protected]

Total Funding:

325.87 M USD

Technology used in webpage:

LetsEncrypt IPv6 New Relic Mobile Optimized FLoC Opt-Out FLoC Drupal Akamai Hosted Adobe Dynamic Tag Management LiveChat

Similar Organizations

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

piqur-therapeutics-logo

PIQUR Therapeutics

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.

salix-pharmaceuticals-logo

Salix Pharmaceuticals

Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.

Current Advisors List

axel-bolte_image

Axel Bolte Member of the Board of Directors @ Nabriva Therapeutics
Board_member

charles-rowland_image

Charles Rowland Member of the Board of Directors @ Nabriva Therapeutics
Board_member
2015-01-01

anja-könig_image

Anja König Board Positions @ Nabriva Therapeutics
Board_member

david-chiswell_image

David Chiswell Chairman @ Nabriva Therapeutics
Board_member
2012-06-01

axel-bolte_image

Axel Bolte Member of the Board of Directors @ Nabriva Therapeutics
Board_member

Current Employees Featured

ted-schroeder_image

Ted Schroeder
Ted Schroeder CEO @ Nabriva Therapeutics
CEO
2018-07-01

denise-pollard-knight_image

Denise Pollard-Knight
Denise Pollard-Knight Director @ Nabriva Therapeutics
Director

not_available_image

Christine Guico-Pabia
Christine Guico-Pabia Chief Medical Officer @ Nabriva Therapeutics
Chief Medical Officer
2021-10-01

Founder

rodger-novak_image

Rodger Novak

Stock Details

Company's stock symbol is NASDAQ:NBRV

Acquisitions List

Date	Company	Article	Price
2018-07-25	Zavante Therapeutics	Zavante Therapeutics acquired by Nabriva Therapeutics	N/A

Investors List

armentum-partners_image

Armentum Partners

Armentum Partners investment in Post-IPO Debt - Nabriva Therapeutics

herculescapital_image

Hercules Capital

Hercules Capital investment in Post-IPO Debt - Nabriva Therapeutics

novartis-venture-fund_image

Novartis Venture Fund

Novartis Venture Fund investment in Series B - Nabriva Therapeutics

gls-ventures_image

GLS Ventures

GLS Ventures investment in Series B - Nabriva Therapeutics

ecor1-capital_image

EcoR1 Capital

EcoR1 Capital investment in Series B - Nabriva Therapeutics

wellcome-trust_image

Wellcome Trust

Wellcome Trust investment in Series B - Nabriva Therapeutics

hbm-healthcare-investments-ag_image

HBM Healthcare Investments AG

HBM Healthcare Investments AG investment in Series B - Nabriva Therapeutics

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series B - Nabriva Therapeutics

phase4-partners_image

Phase4 Partners

Phase4 Partners investment in Series B - Nabriva Therapeutics

vivo-capital_image

Vivo Capital

Vivo Capital investment in Series B - Nabriva Therapeutics

Key Employee Changes

Date	New article
2021-10-01	Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer

Official Site Inspections

http://www.nabriva.com Semrush global rank: 8.11 M Semrush visits lastest month: 365

Host Informations
Whois Informations

Loading ...

More informations about "Nabriva Therapeutics" on Search Engine